TRUFILL n-BCA Liquid Embolic System
Cerenovus, Inc. · Decision date Oct 23, 2026
What did the FDA approve?
The FDA recorded an approval decision on 2026-10-23 for P990040/S037, a PMA supplement to the TRUFILL n-BCA Liquid Embolic System (Cerenovus, Inc.). The supplement is filed under the Normal 180 Day Track No User Fee category with the reason Postapproval Study Protocol. The device category is a tissue adhesive for embolization of brain arteriovenous malformations, with Neurology as the listed specialty and KGG as the product code.
The recorded scope is narrow: this action approves the protocol for the TRUFILL post-approval study, submitted to comply with conditions of approval in the order for P990040/S034. It is not a new approval of the whole system, and the source does not describe protocol contents, study endpoints, enrollment, timelines, or the specific conditions from S034. No FDA documents were included in the source record, so those details remain unknown here.
FDA approval order statement
Approval of the protocol for the TRUFILL post-approval study (PAS). The PAS protocol has been submitted to comply with the conditions of approval outlined in our approval order for P990040/S034.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Neurology
- Decision date
- Oct 23, 2026
- FDA change category
- Postapproval Study Protocol
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P990040/S037
- Regulatory pathway
- PMA supplement
- Applicant
- Cerenovus, Inc.
- Product code
- KGG
- Decision code
- APPR
- Decision date
- Oct 23, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: tissue adhesive for use in embolization of brain arteriovenous malformations.
- Applicant
- Cerenovus, Inc.
- Product code
- KGG
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P990040. Subsequent supplements may change the device or its indications.
FDA decision timeline
P990040 · Original PMA
TRUFILL N-BUTYL CYANOACRYLATE LIQUID EMBOLIC SYSTEM
P990040/S037 received
Application receipt date recorded by FDA.
P990040/S037 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P990040. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P990040
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Cerenovus, Inc. | PMA approval | Sep 25, 2000 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Cerenovus, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 6303 Waterford District Dr., Suite 315, Miami, FL, 33126
Sources and methodology
- Original FDA record: P990040/S037
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records